105 related articles for article (PubMed ID: 26499264)
1. Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.
Arsenic R; Braicu EI; Letsch A; Dietel M; Sehouli J; Keilholz U; Ochsenreither S
BMC Cancer; 2015 Oct; 15():784. PubMed ID: 26499264
[TBL] [Abstract][Full Text] [Related]
2. Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Radosa MP; Häfner N; Camara O; Diebolder H; Mothes A; Winzer H; Jansen L; Dürst M; Runnebaum IB
Int J Gynecol Cancer; 2011 Nov; 21(8):1399-406. PubMed ID: 21897273
[TBL] [Abstract][Full Text] [Related]
3. Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.
Huang KC; Yang J; Ng MC; Ng SK; Welch WR; Muto MG; Berkowitz RS; Ng SW
Eur J Cancer; 2016 Nov; 67():152-163. PubMed ID: 27669502
[TBL] [Abstract][Full Text] [Related]
4. Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer.
Cybulski M; Jarosz B; Nowakowski A; Jeleniewicz W; Kutarska E; Bednarek W; Stepulak A
Anticancer Res; 2015 Mar; 35(3):1715-21. PubMed ID: 25750333
[TBL] [Abstract][Full Text] [Related]
5. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.
Bignotti E; Todeschini P; Calza S; Falchetti M; Ravanini M; Tassi RA; Ravaggi A; Bandiera E; Romani C; Zanotti L; Tognon G; Odicino FE; Facchetti F; Pecorelli S; Santin AD
Eur J Cancer; 2010 Mar; 46(5):944-53. PubMed ID: 20060709
[TBL] [Abstract][Full Text] [Related]
6. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
7. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.
Abdel Azim S; Duggan-Peer M; Sprung S; Reimer D; Fiegl H; Soleiman A; Marth C; Zeimet AG
Oncotarget; 2016 Jun; 7(24):37205-37214. PubMed ID: 27174921
[TBL] [Abstract][Full Text] [Related]
9. Cyclin A1 is highly expressed in aggressive testicular germ cell tumors.
Müller-Tidow C; Diederichs S; Schrader MG; Vogt U; Miller K; Berdel WE; Serve H
Cancer Lett; 2003 Feb; 190(1):89-95. PubMed ID: 12536081
[TBL] [Abstract][Full Text] [Related]
10. [Expression of p21(WAF1) and its relationship with p53 and PCNA protein in epithelial ovarian cancer].
Yan XJ; Liang LZ; Li DC; Li JL; Zhang CQ; Yuan SH
Ai Zheng; 2004 Jan; 23(1):74-80. PubMed ID: 14720380
[TBL] [Abstract][Full Text] [Related]
11. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
13. [Expression of a novel biomarker, MR-1S, in ovarian carcinoma and its biological significance].
Lu RQ; Sun M; Gao X; Guo L
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):176-81. PubMed ID: 22780969
[TBL] [Abstract][Full Text] [Related]
14. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer.
Aldovini D; Demichelis F; Doglioni C; Di Vizio D; Galligioni E; Brugnara S; Zeni B; Griso C; Pegoraro C; Zannoni M; Gariboldi M; Balladore E; Mezzanzanica D; Canevari S; Barbareschi M
Int J Cancer; 2006 Oct; 119(8):1920-6. PubMed ID: 16804906
[TBL] [Abstract][Full Text] [Related]
15. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
16. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.
Müller-Tidow C; Metzger R; Kügler K; Diederichs S; Idos G; Thomas M; Dockhorn-Dworniczak B; Schneider PM; Koeffler HP; Berdel WE; Serve H
Cancer Res; 2001 Jan; 61(2):647-53. PubMed ID: 11212263
[TBL] [Abstract][Full Text] [Related]
17. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
18. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer.
Sharma S; Qian F; Keitz B; Driscoll D; Scanlan MJ; Skipper J; Rodabaugh K; Lele S; Old LJ; Odunsi K
Gynecol Oncol; 2005 Oct; 99(1):183-8. PubMed ID: 16005946
[TBL] [Abstract][Full Text] [Related]
19. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
20. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.
Tammela J; Jungbluth AA; Qian F; Santiago D; Scanlan MJ; Keitz B; Driscoll D; Rodabaugh K; Lele S; Old LJ; Odunsi K
Cancer Immun; 2004 Oct; 4():10. PubMed ID: 15487888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
